Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine

NCT05749926 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

248

Enrollment

OTHER

Sponsor class

Conditions

Vaccine Reaction
COVID-19

Interventions

BIOLOGICAL: Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)
BIOLOGICAL: VidPrevtyn® Beta vaccine (Sanofi/GSK)

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]